natgillin/translations-raw huggingface dataset:
Rixathon is usually taken together with another medicine called methotrexate. 
Rixathon se običajno jemlje skupaj z zdravilom, imenovanim metotreksat.
How much and how often you will receive your treatment a) If you are being treated for non-Hodgkin's Lymphoma 
Koliko zdravila boste dobili in kako pogosto a) Če se zdravite zaradi ne-Hodgkinovega limfoma
Before giving a subsequent course of Rixathon treatment, patients should be re-evaluated for any potential risk for infections. 
Pred dajanjem nadaljnjega cikla zdravila Rixathon je treba bolnike ponovno oceniti glede možnega tveganja za okužbe.
The HCP Alert card addressing the correct use of Rixathon contains the following key elements: - The advice that Rixathon is for intravenous use only and recommendations how to ensure this route of administration 
Opozorilna kartica za zdravstvenega delavca, ki obravnava pravilno uporabo zdravila Rixathon, vsebuje naslednje ključne vsebine: - navedbo, da je zdravilo Rixathon namenjeno samo za intravensko uporabo, in priporočila, kako zagotoviti, da se uporablja ta pot uporabe
Data from extended follow up of patients in the study (median follow-up 9 years) confirmed the longterm benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT, and TNCT (Table 7). 
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z rituksimabom glede na PFS, EFS, TNLT in TNCT
The ADRs identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known”. 
Neželeni učinki, ki so jih opazili samo po prihodu zdravila na trg in za katere pogostnosti ni mogoče oceniti, so navedeni v „neznana“.
Mild or moderate infusion-related reactions (IRR) (section 4.8) usually respond to a reduction in the rate of infusion. 
Blage ali zmerne reakcije, povezane z infuzijo (poglavje 4.8), lahko običajno zmanjšamo z manjšim infuzijskim pretokom.
• taste problems - such as changes in the way things taste 
• motnje okušanja - na primer spremenjen okus stvari,
Rixathon is indicated in adults for the following indications: 
Zdravilo Rixathon je pri odraslih indicirano za naslednje indikacije:
Rixathon should be administered under the close supervision of an experienced healthcare professional, and in an environment where full resuscitation facilities are immediately available (see section 4.4). 
Zdravilo Rixathon je treba dajati pod nadzorom izkušenega zdravnika in v okolju, kjer so vsi pripomočki za oživljanje nemudoma na voljo (glejte poglavje 4.4).
This antigen does not internalise upon antibody binding and is not shed from the cell surface. 
Po vezavi s protitelesom ne vstopa v notranjost celice, niti se ne odcepi s celične površine.
The primary objective for the study was complete remission (complete epithelialisation and absence of new and/or established lesions) at month 24 without the use of prednisone therapy for two months or more (CRoff for ≥2 months). 
Primarni cilj študije je bila popolna remisija (CR - complete remission) (popolna epitelizacija in odsotnost novih in/ali razvitih lezij) po 24 mesecih brez uporabe prednizonskega zdravljenja v obdobju dveh mesecev ali več (CRoff za ≥ 2 meseca).
Figure 1: Change from baseline of DAS28-ESR by baseline autoantibody status 
Slika 1: Sprememba v DAS28-ESR od izhodišča glede na izhodiščno stanje protiteles
Your doctor will check if you should have any vaccines before you receive Rixathon. 
Vaš zdravnik bo preveril, ali bi morali biti cepljeni, preden boste dobili zdravilo Rixathon.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Rixathon slows down the damage to your joints caused by rheumatoid arthritis and improves your ability to do normal daily activities. 
Zdravilo Rixathon upočasni nastanek okvar sklepov, ki so posledica revmatoidnega artritisa, ter izboljša vašo sposobnost za opravljanje običajnih dnevnih aktivnosti.
Table 16 Percentage of patients who achieved complete remission at 6 months (intent-to-treat population*) 
Odstotek bolnikov, ki so po 6 mesecih dosegli popolno remisijo (populacija, ki so jo nameravali zdraviti*)
• tight or painful muscles 
• napete ali boleče mišice,
Patients with CLL have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood. 
Bolniki s KLL imajo preveč nenormalnih limfocitov, ki se kopičijo predvsem v kostnem mozgu in krvi.
Treatment with rituximab in combination with methotrexate over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA, as indicated by ACR, DAS28-ESR and EULAR responses which was evident in all patient populations studied (Figure 2). 
Zdravljenje z rituksimabom v kombinaciji z metotreksatom v več ciklih je prineslo stalno izboljšanje kliničnih znakov in simptomov RA, kot so pokazali odzivi po ACR, DAS28-ESR in EULAR; to je bilo opazno v vseh raziskovanih populacijah bolnikov (slika 2).
Seropositive patients also had a significantly greater decrease in DAS28-ESR compared to seronegative patients (Figure 1). 
Seropozitivni bolniki so imeli tudi značilno večje zmanjšanje v DAS28ESR kot seronegativni bolniki (slika 1).
In a long-term observational safety study, 97 GPA/MPA patients received treatment with rituximab (mean of 8 infusions [range 1-28]) for up to 4 years, according to their physician's standard practice and discretion. 
V dolgoročni opazovalni študiji varnosti je 97 bolnikov z GPA/MPA prejemalo zdravljenje z rituksimabom (v povprečju 8 infuzij [razpon od 1 do 28]) do 4 leta, v skladu s standardno prakso in presojo njihovega zdravnika.
In patients where the treatment is working, Rixathon may be used as a maintenance treatment for 2 years after completing the initial treatment. 
Pri bolnikih, pri katerih takšno zdravljenje deluje, je mogoče zdravilo Rixathon uporabljati kot vzdrževalno zdravljenje še dve leti po dokončanju začetnega zdravljenja.
• If you respond well to treatment, you may be given Rixathon as a maintenance treatment every 2 or 3 months for two years. 
• Če se boste dobro odzvali na zdravljenje, boste lahko zdravilo Rixathon dobivali kot vzdrževalno zdravljenje na dva meseca ali tri, in sicer dve leti.
A small proportion of patients had prolonged peripheral B cell depletion lasting 2 years or more after their last dose of rituximab. 
Pri majhnem deležu bolnikov je bil upad števila perifernih celic B dolgotrajen, trajal je 2 leti ali več po zadnjem odmerku rituksimaba.
9.25 years 
9,25 let
The proportion of patients experiencing an infusionrelated reaction was 29% (11 patients), 40% (15 patients), 13% (5 patients), and 10% (4 patients) following the first, second, third, and fourth infusions, respectively. 
Delež bolnikov, ki se jim je pojavila z infundiranjem povezana reakcija, je bil po prvem infundiranju 29 % (11 bolnikov), po drugem 40 % (15 bolnikov), po tretjem 13 % (5 bolnikov) in po četrtem 10 % (4 bolniki).
GLSG'00 CHOP, 205 R-CHOP, 223 18 
CHOP: 205 R-CHOP: 223
This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) during and after the 4 week induction course of Rixathon treatment. 
1 mg/kg/dan prednizona peroralno (odmerek ne sme preseči 80 mg/dan in ga je treba zmanjšati, kolikor hitro je mogoče glede na klinične potrebe) med in po 4-tedenskem indukcijskem zdravljenju z zdravilom Rixathon.
• raised blood pressure 
• zvišan krvni tlak,
2 Frequency category derived from post-marketing data. 
2Pogostnost pridobljena iz podatkov pridobljenih po prihodu zdravila na trg.
The majority of patients (81%) showed signs of B cell return, with counts > 10 cells/μL by month 12, increasing to 87% of patients by month 18. 
Pri večini bolnikov (81 %) se je število celic B ponovno povečalo na > 10 celic/µl do 12. meseca, do 18. meseca pa še pri večjem, 87-% deležu bolnikov.
Mean change in SF-36 PHS 
Povprečna sprememba SF-36 PHS
Of the patients originally receiving methotrexate alone, 81% received rituximab either as rescue between weeks 16-24 or in the extension trial, before week 56. 
Od bolnikov, ki so prvotno dobivali samo metotreksat, jih je 81 % dobilo rituksimab kot rešilno zdravilo (rescue) med 16. in 24. tednom ali v okviru nadaljevalne študije pred 56. tednom.
If a patient develops PML, the dosing of Rixathon must be permanently discontinued. 
Če se pri bolniku razvije PML, je treba uporabo zdravila Rixathon dokončno ukiniti.
Number of responders (response rate [%]) ap-value is from Fisher's exact test with mid-p correction b 95% confidence interval is corrected Newcombe interval 
Število odzivnih (delež odziva [%]) a Vrednost p je vrednost iz Fisherjevega eksaktnega testa s sredinskim popravkom p. b 95-% interval zaupanja je korigiran Newcombov interval.
The cells that are affected by Rixathon help to fight infection and you should wait until the infection has passed before you are given Rixathon. 
Celice, ki jih zdravilo Rixathon uniči, pomagajo pri borbi proti okužbam, zato morate počakati, da se okužba pozdravi, preden prejmete zdravilo Rixathon.
If you respond well to treatment, you may be given Rixathon as a maintenance treatment. 
Če se boste na zdravilo dobro odzvali, boste lahko zdravilo Rixathon prejemali kot vzdrževalno zdravljenje.
During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2%) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle. 
Med obdobjem zdravljenja (faza indukcijskega zdravljenja, ki je obsegalo R-CHOP vsaj osem ciklov) so se pri štirih bolnikih (2 %), zdravljenih z R-CHOP, ki so vsi imeli kardiovaskularne dejavnike tveganja, med prvim ciklom zdravljenja pojavili trombembolični cerebrovaskularni dogodki.
The highest intravenous dose of rituximab tested in humans to date is 5,000 mg (2,250 mg/m²), tested in a dose escalation study in patients with chronic lymphocytic leukaemia. 
Največji do zdaj preizkušen intravenski odmerek rituksimaba pri človeku je 5.000 mg (2.250 mg/m2), preizkušen v študiji povečevanja odmerka pri bolnikih s kronično limfocitno levkemijo.
Rituximab is not indicated for these patients, since the safety data about long-term rituximab treatment are insufficient, in particular concerning the risk of development of malignancies and PML. 
Rituksimab ni indiciran za uporabo pri teh bolnikih zaradi nezadostnih podatkov o varnosti dolgoročnega zdravljenja z rituksimabom, še posebej v zvezi s tveganjem za razvoj malignih bolezni ter PML.
At week 24, patients who were seropositive to RF and/or anti-CCP at baseline had a significantly increased probability of achieving ACR20 and 50 responses compared to seronegative patients (p=0.0312 and p=0.0096) (Table 15). 
Po 24 tednih so imeli bolniki, ki so bili izhodiščno seropozitivni za RF in/ali anti-CCP, značilno večjo verjetnost, da dosežejo odziv ACR20 in 50, v primerjavi s seronegativnimi bolniki (p = 0,0312 in p = 0,0096) (preglednica 15).
This is mostly accounted for by IRRs (most frequent during the first treatment course), RA exacerbation and infections, all of which were more frequent in the first 6 months of treatment. 
To gre v glavnem pripisati reakcijam, povezanim z infuzijo (ki se najpogosteje pojavljajo v prvem ciklu zdravljenja), poslabšanju revmatoidnega artritisa in okužbam; vse našteto se je pogosteje pojavljalo v prvih 6 mesecih zdravljenja.
10.49 years 
10,49 let
Patients were between 19 and 79 years of age and had not received prior therapies for pemphigus. 
19 do 79 let in predhodno niso prejemali zdravljenja za pemfigus.
This is because there is not much information about the use of rituximab in children and young people. 
O uporabi rituksimaba pri otrocih in mladostnikih namreč ni veliko informacij.
The incidence of thrombocytopenia was low (< 1%, grade 3/4) and was not different between treatment arms. 
Incidenca trombocitopenije je bila nizka (< 1 % 3. ali 4. stopnje) in se med zdravljenima skupinama ni razlikovala.
Initiate at a rate of 250 mg/hour for the first 30 minutes and then 600 mg/hour for the next 90 minutes. 
Začetna hitrost infundiranja je 250 mg/h prvih 30 minut in nato 600 mg/h naslednjih 90 minut.
Based on the mechanism of action of rituximab and the knowledge that B cells play an important role in maintaining normal immune response, patients have an increased risk of infection following rituximab therapy (see section 5.1). 
Glede na mehanizem delovanja rituksimaba in dejstvo, da imajo celice B pomembno vlogo pri vzdrževanju normalnega imunskega odziva, imajo lahko bolniki, ki se zdravijo z rituksimabom, povečano tveganje za okužbe (glejte poglavje 5.1).
B lymphocytes are involved in the cause of some of the symptoms you have. 
Limfociti B sodelujejo pri nastanku nekaterih simptomov, ki jih imate.
Rituximab N=505 
rituksimab n = 505
Rituximab maintenance treatment reduced the risk of death by 56% (95% CI; 22% - 75%). 
Vzdrževalno zdravljenje z rituksimabom je zmanjšalo tveganje za smrt za 56 % (95-% interval zaupanja: 22-75 %).
When should I not have Rixathon? 
Kdaj ne smete prejeti zdravila Rixathon?
Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia. 
b) kronične limfocitne levkemije Kronična limfocitna levkemija (KLL) je najbolj pogosta oblika levkemije pri odraslih.
Mean change in HAQ-DI 
Povprečna sprememba HAQ-DI
Other rarely-reported side-effects due to rituximab include a decreased number of white cells in the blood (neutrophils) that help to fight against infection. 
Drugi neželeni učinki rituksimaba, o katerih so poročali redko, vključujejo zmanjšano število belih krvnih celic (nevtrofilcev), ki pomagajo v boju proti okužbam.
Treatment difference (rituximabcyclophosphamide) 
razlika zdravljenj (rituksimabciklofosfamid)
• low number of red blood cells (anaemia) 
• nizko število rdečih krvnih celic (anemija),
In a further clinical study, a total of 57 severe, active GPA and MPA patients in disease remission were treated with rituximab for the maintenance of remission (see section 5.1). 
V nadaljnji klinični študiji so skupno 57 bolnikov s hudo aktivno GPA in MPA v remisiji bolezni zdravili z rituksimabom za vzdrževanje remisije (glejte poglavje 5.1).
Skin papilloma * Infusion-related reactions included symptoms collected on the next scheduled visit after each infusion, and adverse events occurring on the day of or one day after the infusion. 
* Z infundiranjem povezane reakcije so vključevale simptome, zbrane ob naslednjem načrtovanem obisku po vsaki infuziji, in neželene dogodke, ki so se pojavili na dan infuzije ali en dan po njej.
Therefore vaccination with live virus vaccines is not recommended whilst on Rixathon or whilst peripherally B cell depleted. 
Cepljenje z živimi virusnimi cepivi zato ni priporočljivo med zdravljenjem z zdravilom Rixathon ali medtem, ko je število perifernih celic B zmanjšano.
• pain in the muscles or in the hands or feet 
• bolečina v mišicah ali dlaneh ali stopalih,
Infusion-related adverse reactions of all kinds have been observed in 77% of patients treated with rituximab (including cytokine release syndrome accompanied by hypotension and bronchospasm in 10% of patients) see section 4.8. 
Z infuzijo povezane neželene reakcije vseh vrst so opazili pri 77 % bolnikov, ki so se zdravili z rituksimabom (vključno s sindromom sproščanja citokinov, ki sta ga spremljala hipotenzija in bronhospazem pri 10 % bolnikov), glejte poglavje 4.8.
▼This medicine is subject to additional monitoring. 
Za to zdravilo se izvaja dodatno spremljanje varnosti.
There are no data on the safety of rituximab in patients with moderate heart failure (NYHA class III) or severe, uncontrolled cardiovascular disease. 
Podatkov o varnosti rituksimaba pri bolnikih z zmernim srčnim popuščanjem (III. razred NYHA) ali hudo, neobvladljivo boleznijo srca ni.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and very rare (< 1/10,000). 
Pogostnost je opredeljena kot zelo pogosta (≥ 1/10), pogosta (≥ 1/100 do < 1/10), občasna (> 1/1.000 do ≤ 1/100) in zelo redka (≤ 1/10.000).
The available data indicate that the rate of clinically relevant infection is unchanged when such therapies are used in patients previously treated with rituximab, however patients should be closely observed for signs of infection if biologic agents and/or DMARDs are used following rituximab therapy. 
Podatki, ki so na voljo, nakazujejo, da je pojavnost klinično pomembnih okužb nespremenjena, ko ta zdravila uporabimo pri bolnikih, ki so jih prej zdravili z rituksimabom, vendar jih moramo skrbno opazovati glede znakov okužbe, če po zdravljenju z rituksimabom prejmejo biološka zdravila in/ali DMARD.
Table 7 Overview of efficacy results for rituximab maintenance vs. observation at the protocol-defined primary analysis and after 9 years median follow-up (final analysis) 
Pregled učinkovitosti vzdrževalnega zdravljenja z rituksimabom v primerjavi z opazovanjem v času primarne analize, določene s protokolom, in po mediani spremljanja 9 let (končna analiza)
When you are treated with Rixathon in combination with chemotherapy, you will receive Rixathon infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total. 
Ko se boste zdravili z zdravilom Rixathon v kombinaciji s kemoterapijo, boste dobili infuzijo zdravila Rixathon 0. dan 1. cikla in nato 1. dan vsakega naslednjega cikla, skupaj 6 ciklov.
Significant improvement in health related quality of life was also demonstrated with significant improvement in both the physical health score (PHS) and mental health score (MHS) of the SF-36. 
Ugotovljeno je bilo tudi značilno izboljšanje zdravstvenih kazalcev kakovosti življenja z značilnim izboljšanjem ocene telesnega zdravja (PHS, Physical Health Score) in duševnega zdravja (MHS,
This is because Rixathon may pass into breast milk. 
Zdravilo Rixathon namreč lahko prehaja v materino mleko.
There was a higher incidence of grade 3/4 ADRs in patients with bulky disease than in patients without bulky disease (25.6% vs. 15.4%). 
Bolniki z obsežno boleznijo so imeli višjo incidenco neželenih učinkov (3. ali 4. stopnje) kot bolniki brez obsežne bolezni (25,6 % v primerjavi s 15,4 %).
There are limited data from clinical trials to fully assess the safety of the sequential use of other DMARDs (including TNF inhibitors and other biologics) following rituximab (see section 4.5). 
Iz kliničnih preskušanj ni zadostnih podatkov za popolno oceno varnosti uporabe drugih DMARD (vključno z zaviralci TNF in drugimi biološkimi zdravili), ki sledijo zdravljenju z rituksimabom (glejte poglavje 4.5).
• heart beating faster than normal 
• hitrejše bitje srca kot običajno.
Respiratory system Cases of interstitial lung disease, some with fatal outcome have been reported. 
Poročali so o primerih intersticijske bolezni pljuč, nekateri so bili smrtni.
The safety information collected during post marketing experience reflects the expected adverse reaction profile as seen in clinical trials for rituximab (see section 4.4). 
Podatki o varnosti, zbrani v obdobju po prihodu zdravila na trg, odražajo pričakovani profil neželenih učinkov, kot so ga opazili v kliničnih preskušanjih z rituksimabom (glejte poglavje 4.4).
However, because maternal IgG is excreted in human milk, and rituximab was detectable in milk from lactating monkeys, women should not breast-feed while treated with Rixathon and for 12 months following Rixathon treatment. 
A zaradi dejstva, da se materini IgG izločajo v materino mleko, in da so rituksimab našli v mleku doječih opic, ženske med zdravljenjem z zdravilom Rixathon in 12 mesecev po njem ne smejo dojiti.
Figure 4: Number of patients who were off or on minimal corticosteroid (≤10mg/day) therapy over time 
Slika 4: Število bolnikov brez kortikosteroidnega zdravljenja ali z minimalnim kortikosteroidnim zdravljenjem (≤ 10 mg/dan) glede na čas zdravljenja
Abbreviation: NS, non-significant 
Kratica: NS, ni značilno (Not Significant).
• infections such as herpes infections and eye infection 
• okužbe, kot so okužbe z virusom herpes in očesne okužbe,
These findings were replicated at week 48, where autoantibody seropositivity also significantly increased the probability of achieving ACR70. 
48. teden, ko je seropozitivnost prav tako značilno povečala verjetnost za doseganje odziva ACR70.
Prednisone tapering was to be completed by 6 months from the start of trial treatment. 
Postopno zmanjševanje prednizona so morali končati do 6 mesecev po začetku raziskovanega zdravljenja.
Some cases of late neutropenia occurring more than four weeks after the last infusion of rituximab were reported. 
Poročali so o posameznih primerih pozne nevtropenije, ki se je pojavila več kot 4 tedne po zadnji infuziji rituksimabom.
Severe (grade 3/4) neutropenia was reported in 4.2%, anaemia in 1.1% and thrombocytopenia in 1.7% of the patients. 
Huda nevtropenija (3. ali 4. stopnje) se je pojavila pri 4,2 % bolnikov, anemija pri 1,1 % in trombocitopenija pri 1,7 % bolnikov.
Some vaccines should not be given at the same time as Rixathon or in the months after you receive Rixathon. 
Nekatera cepiva se ne smejo dajati sočasno z zdravilom Rixathon ali nekaj mesecev po prejetju tega zdravila.
The incidence of infusionrelated symptoms decreases substantially with subsequent infusions and is less than 1% after eight doses of rituximab. 
Incidenca simptomov, povezanih z infuzijo, se z nadaljnjimi infuzijami bistveno zmanjšuje in je po osmih odmerkih rituksimaba manjša kot 1 %.
Reactivation of hepatitis B infection has also been very rarely reported in RA patients receiving rituximab (see section 4.4). 
reaktivaciji okužbe z virusom hepatitisa B so zelo redko poročali tudi pri bolnikih z revmatoidnim artritisom, ki so prejemali rituksimab (glejte poglavje 4.4).
Pharmacotherapeutic group: antineoplastic agents, monoclonal antibodies, ATC code: L01X C02 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, monoklonska protitelesa, oznaka ATC: L01X C02.
• heart problems - such as heart attack, uneven or fast heart rate 
• težave s srcem - na primer srčni infarkt, neredno ali hitro bitje srca,
Gastrointestinal perforation in some cases leading to death has been observed in patients receiving rituximab for treatment of non-Hodgkin lymphoma. 
Perforacijo prebavil, ki je v nekaterih primerih povzročila smrt, so opazili pri bolnikih, ki so prejemali rituksimab za zdravljenje ne-Hodgkinovega limfoma.
The majority of patients were ANCApositive at diagnosis or during the course of their disease; had histologically confirmed necrotizing small-vessel vasculitis with a clinical phenotype of GPA/MPA, or renal limited ANCA-associated vasculitis; or both. 
Večina bolnikov je bila ob postavitvi diagnoze ali med potekom bolezni ANCA-pozitivnih; imeli so histološko potrjen nekrotizirajoč vaskulitis malih žil s kliničnim fenotipom GPA/MPA, ledvično omejen z ANCA
• lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG) in the blood which help protect against infection 
• zmanjšana imunost - zaradi manjše koncentracije protiteles, imenovanih imunoglobulini (IgG), v krvi; ta protitelesa pomagajo pri zaščiti proti okužbam.
The proportion of patients with IgG levels below the LLN was about 60% in the rituximab group throughout the 2 year treatment period, while it decreased in the observation group (36% after 2 years). 
Delež bolnikov s koncentracijo IgG pod spodnjo mejo normalne vrednosti je bil med 2-letnim zdravljenjem približno 60 % v skupini, ki je prejemala rituksimab, v opazovani skupini pa se je zmanjšal (36 % po dveh letih).
This is because in a few cases, Rixathon could cause hepatitis B to become active again, which can be fatal in very rare cases. 
V maloštevilnih primerih namreč lahko bolezen zaradi zdravila Rixathon ponovno izbruhne; to je lahko v zelo redkih primerih smrtno.